echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > During the 13th Five Year Plan period, the reform measures of the pharmaceutical industry were continuous

    During the 13th Five Year Plan period, the reform measures of the pharmaceutical industry were continuous

    • Last Update: 2016-05-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: according to the data released at the 5th (enlarged) meeting of the 7th session of China Pharmaceutical Enterprise Management Association and the 29th China Pharmaceutical Industry Development Summit Forum held on May 6, 2016 in the economic reference newspaper, "12th Five Year Plan" Since then, the main business income, total foreign trade, total profit and total investment of China's pharmaceutical industry have continued to maintain stable growth Experts at the meeting said that the growth of the pharmaceutical industry is becoming more and more obvious driven by innovation from full coverage in the past At present, the innovation ability of the pharmaceutical industry is relatively weak, and scientific and technological innovation needs to be strengthened In addition, with the implementation of "two vote system" and other policies, the pharmaceutical circulation industry will face changes According to the data of stable growth during the 12th Five Year Plan period, the pharmaceutical industry in China has developed steadily since the 12th Five Year Plan period The main business income has reached more than 200 billion yuan, and the industrial added value of the pharmaceutical manufacturing industry above designated size has increased by 9.9% year-on-year, 3.8 percentage points higher than that of the same period The total import and export trade volume has reached more than 100 billion yuan, an increase of 5% year-on-year, and the total profit has reached nearly 280 billion yuan, an increase of 12.5% year-on-year In terms of drug distribution and sales, the average growth rate during the 12th Five Year Plan period was 17%, and the growth rate remained double-digit The retail sales of drugs doubled from 2010 to 2014, reaching more than 150 billion yuan Although specific statistics for 2015 have not yet been released, experts expect that it will reach more than 170 billion yuan But at the same time, the pharmaceutical industry is facing a series of changes Guo yunpei, vice president of China Pharmaceutical Enterprise Management Association, said that the growth of the pharmaceutical industry is becoming more and more obvious driven by innovation from full coverage in the past With the deepening of medical reform, we will accelerate the reform of public hospitals in the future, cancel the drug markup in an all-round way, realize the two vote system of drug sales, promote the second price negotiation of drugs, open up the prescription selection of patients, reform the drug payment system, revise the drug catalog of medical insurance, sink the high-quality medical resources, encourage doctors to practice more and implement hierarchical diagnosis and treatment There will also be a series of policy changes in the field of drugs, such as self-examination and verification of drug clinical trials, drug consistency evaluation, suspension of the implementation of electronic supervision code, and the impact of the current medical Internet and medical Internet on traditional medicine Experts attending the meeting generally agreed that one of the short boards facing the pharmaceutical industry at present is the relatively weak innovation ability, and scientific and technological innovation needs to be strengthened At present, the average R & D investment of the top 50 pharmaceutical companies in the world accounts for 17% of the sales revenue, while our large pharmaceutical companies only account for 5%, with an average level of less than 2% The R & D investment of domestic medical devices is about 3%, so more than 60% of the high-end medical device market with high technology content and high sales price is occupied by foreign-funded products, and more than half of the top 10 pharmaceutical manufacturers are foreign-funded enterprises In addition, the industry concentration is still relatively low Among the more than 10000 medical production enterprises in China, there are only more than 1000 enterprises above Designated Size, less than 20 enterprises with sales revenue of more than 1 billion, and less than 15 pharmaceutical enterprises with sales revenue of more than 5400 Enterprises above Designated Size with sales revenue of more than 10 billion There are many, small, scattered enterprises and low concentration, which are not conducive to the improvement of the technological innovation ability and the competitiveness of the international market of China's pharmaceutical industry Wang Hongguang, Research Institute of development strategy of the Ministry of science and technology, said that the pharmaceutical industry has the greatest potential, the fastest speed and the highest efficiency If we judge the trend of the industry, it is still in the golden age One of the reasons is that it is impossible for innovation ability to achieve rapid development in a short period of time It needs to accumulate, and there will be a gradual process, "so the industry is neither good nor bad." But on the other hand, the situation of the relative surplus of old drugs and the surplus of general drugs may not be reversed in the short term It is normal that good drugs will never be enough The head of the industry coordination department of the national development and Reform Commission said that the next step of the Commission will be to increase innovation support In addition to the traditional financial support within the central budget, the first domestic industrial investment fund and a new special construction fund were established last year, which took the form of capital loan In the special construction funds, the green transformation of innovative drugs, high-end medical devices and chemical raw materials, including the relocation and transformation of hazardous chemicals, will be the key support direction At the same time, it will support the manufacturing and demonstration application of industrial robots, promote the construction of intelligent factories, and support the creation of new materials The 13th Five Year Plan period is the key period of medical reform, and it is also an important period for the industry to change its development mode and establish a modern circulation system In the document of promoting the healthy development of the pharmaceutical industry issued by the general office of the State Council, the establishment of a modern pharmaceutical circulation system is mentioned Wen Zaixing, former inspector of the market order Department of the Ministry of Commerce, said that there might be new measures to separate medicine "At present, the policy orientation is to promote that hospital prescriptions can be purchased in the society, and the whole retail terminal may continue to increase I have noticed that in recent years, pharmaceutical enterprises, including many foreign pharmaceutical enterprises, have been chasing after retail pharmacies and established a retail team " "If the state's policy on the" two ticket system "and the outflow of prescriptions is strictly implemented, prescriptions will flow out of hospitals, which will benefit drugstores or pharmaceutical e-commerce, many of which are actively preparing for the sale of prescription drugs," Wen said In addition, the national promotion trend of "two vote system" has become more and more clear, which will bring a new round of structural adjustment to the whole domestic drug retail market Niu Zhengqian, vice president of the pharmaceutical enterprise management association, said that if the "two vote system" is implemented, unlike most people who think that large commercial companies will get huge development opportunities, he believes that the local and municipal level grass-roots commercial companies will have more advantages The reason is that in the market of grassroots cities and counties with wide geographical distribution, large pharmaceutical commercial companies have not been well covered, and pharmaceutical companies can only directly issue invoices to prefecture and city level companies if they want to enter the grassroots market If patients choose to buy drugs in hospitals or retail pharmacies independently, combined with the fact that the level of basic medical insurance is not high, it is expected that at most 25% of hospital drug sales will be squeezed into retail or e-commerce, so as to meet the qualification standard of drug proportion.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.